Literature DB >> 21424761

Implication of CCR2 chemokine receptor in cocaine-induced sensitization.

Jean Marc Trocello1, William Rostene, Stephane Melik-Parsadaniantz, David Godefroy, Emmanuel Roze, Patrick Kitabgi, William A Kuziel, Sylvie Chalon, Jocelyne Caboche, Emmanuelle Apartis.   

Abstract

Cocaine-induced sensitization induces long-term neuroplastic changes in the striatum. Among these, extracellular signal-regulated kinase (ERK) is a fundamental component in striatal gene and epigenetic regulation and plays an important role in reward processes. As previous studies suggested that the chemokine CCL2 enhanced striatal dopamine release and as its cognate CCR2 receptor was located in brain structures implicated in cocaine reward, we tested the hypothesis that CCR2/CCL2 could be involved in cocaine-induced behavioral response. We used CCR2 knockout mice (CCR2(-/-)) and studied two crucial steps in cocaine sensitization: locomotor activity in sensitized mice and ERK activation in the striatum. We show that locomotor sensitization is significantly reduced in CCR2(-/-) mice as well as the dopamine transporter regulation and the cocaine-induced p-ERK striatal activation. Taken together, our results suggest that CCR2 receptor is involved in cocaine sensitization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21424761     DOI: 10.1007/s12031-011-9508-4

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  21 in total

Review 1.  MAPK cascade signalling and synaptic plasticity.

Authors:  Gareth M Thomas; Richard L Huganir
Journal:  Nat Rev Neurosci       Date:  2004-03       Impact factor: 34.870

2.  Epigenetic modulation at the CCR2 gene correlates with the maintenance of behavioral sensitization to methamphetamine.

Authors:  Daigo Ikegami; Minoru Narita; Satoshi Imai; Kazuhiko Miyashita; Rie Tamura; Michiko Narita; Shigemi Takagi; Akiko Yokomizo; Hideyuki Takeshima; Takayuki Ando; Katsuhide Igarashi; Jun Kanno; Naoko Kuzumaki; Toshikazu Ushijima; Tsutomu Suzuki
Journal:  Addict Biol       Date:  2010-07       Impact factor: 4.280

3.  Morphine modulates chemokine gene regulation in normal human astrocytes.

Authors:  Supriya D Mahajan; Stanley A Schwartz; Ravikumar Aalinkeel; Ram P Chawda; Donald E Sykes; Madhavan P N Nair
Journal:  Clin Immunol       Date:  2005-06       Impact factor: 3.969

4.  Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease.

Authors:  S Chalon; P Emond; S Bodard; M P Vilar; C Thiercelin; J C Besnard; D Guilloteau
Journal:  Synapse       Date:  1999-02       Impact factor: 2.562

5.  Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants.

Authors:  Anne-Gaëlle Corbillé; Emmanuel Valjent; Giovanni Marsicano; Catherine Ledent; Beat Lutz; Denis Hervé; Jean-Antoine Girault
Journal:  J Neurosci       Date:  2007-06-27       Impact factor: 6.167

Review 6.  Rapid regulation of the dopamine transporter: role in stimulant addiction?

Authors:  Nancy R Zahniser; Alexander Sorkin
Journal:  Neuropharmacology       Date:  2004       Impact factor: 5.250

7.  Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release.

Authors:  A Guyon; D Skrzydelski; I De Giry; C Rovère; G Conductier; J M Trocello; V Daugé; P Kitabgi; W Rostène; J L Nahon; S Mélik Parsadaniantz
Journal:  Neuroscience       Date:  2009-05-27       Impact factor: 3.590

8.  Early signal transduction by the receptor to the chemokine monocyte chemotactic protein-1 in a murine T cell hybrid.

Authors:  P M Dubois; D Palmer; M L Webb; J A Ledbetter; R A Shapiro
Journal:  J Immunol       Date:  1996-02-15       Impact factor: 5.422

9.  Cocaine-mediated alteration in tight junction protein expression and modulation of CCL2/CCR2 axis across the blood-brain barrier: implications for HIV-dementia.

Authors:  Navneet K Dhillon; Fuwang Peng; Sirosh Bokhari; Shannon Callen; Sun-Hye Shin; Xuhui Zhu; Kee-Jun Kim; Shilpa J Buch
Journal:  J Neuroimmune Pharmacol       Date:  2007-11-29       Impact factor: 4.147

Review 10.  Chemokine action in the nervous system.

Authors:  Richard J Miller; William Rostene; Emanuelle Apartis; Ghazal Banisadr; Knut Biber; Erin D Milligan; Fletcher A White; Ji Zhang
Journal:  J Neurosci       Date:  2008-11-12       Impact factor: 6.167

View more
  10 in total

1.  Chemokine CCR5 and cocaine interactions in the brain: Cocaine enhances mesolimbic CCR5 mRNA levels and produces place preference and locomotor activation that are reduced by a CCR5 antagonist.

Authors:  Sunil U Nayak; Stephanie Cicalese; Chris Tallarida; Chicora F Oliver; Scott M Rawls
Journal:  Brain Behav Immun       Date:  2019-09-23       Impact factor: 7.217

Review 2.  Neuroimmune mechanisms of psychostimulant and opioid use disorders.

Authors:  Rebecca S Hofford; Scott J Russo; Drew D Kiraly
Journal:  Eur J Neurosci       Date:  2018-09-26       Impact factor: 3.386

3.  Multi-chemokine receptor antagonist RAP-103 inhibits opioid-derived respiratory depression, reduces opioid reinforcement and physical dependence, and normalizes opioid-induced dysregulation of mesolimbic chemokine receptors in rats.

Authors:  Angela R Bongiovanni; Pingwei Zhao; Saadet Inan; Sonita Wiah; Aryan Shekarabi; Daniel J Farkas; Mia N Watson; Mathieu E Wimmer; Michael R Ruff; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2022-07-11       Impact factor: 4.852

4.  Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder.

Authors:  Nerea Requena-Ocaña; María Flores-Lopez; Esther Papaseit; Nuria García-Marchena; Juan Jesús Ruiz; Jesús Ortega-Pinazo; Antonia Serrano; Francisco Javier Pavón-Morón; Magí Farré; Juan Suarez; Fernando Rodríguez de Fonseca; Pedro Araos
Journal:  Biomedicines       Date:  2022-04-20

Review 5.  Glial mechanisms underlying substance use disorders.

Authors:  K E Linker; S J Cross; F M Leslie
Journal:  Eur J Neurosci       Date:  2018-10-22       Impact factor: 3.386

Review 6.  Chemokines, cytokines and substance use disorders.

Authors:  Olivia C Ahearn; Mia N Watson; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2021-01-08       Impact factor: 4.492

7.  Plasma Chemokines in Patients with Alcohol Use Disorders: Association of CCL11 (Eotaxin-1) with Psychiatric Comorbidity.

Authors:  Nuria García-Marchena; Pedro Fernando Araos; Vicente Barrios; Laura Sánchez-Marín; Julie A Chowen; María Pedraz; Estela Castilla-Ortega; Pablo Romero-Sanchiz; Guillermo Ponce; Ana L Gavito; Juan Decara; Daniel Silva; Marta Torrens; Jesús Argente; Gabriel Rubio; Antonia Serrano; Fernando Rodríguez de Fonseca; Francisco Javier Pavón
Journal:  Front Psychiatry       Date:  2017-01-18       Impact factor: 4.157

8.  CXCR4 inhibition with AMD3100 attenuates amphetamine induced locomotor activity in adolescent Long Evans male rats.

Authors:  Briana Mason; Corey Calhoun; Victoria Woytowicz; Latifa Pina; Roshninder Kanda; Curtis Dunn; Antonio Alves; S Tiffany Donaldson
Journal:  PLoS One       Date:  2021-03-01       Impact factor: 3.240

Review 9.  Epigenetic Regulatory Dynamics in Models of Methamphetamine-Use Disorder.

Authors:  Subramaniam Jayanthi; Michael T McCoy; Jean Lud Cadet
Journal:  Genes (Basel)       Date:  2021-10-14       Impact factor: 4.096

10.  A molecular profile of cocaine abuse includes the differential expression of genes that regulate transcription, chromatin, and dopamine cell phenotype.

Authors:  Michael J Bannon; Magen M Johnson; Sharon K Michelhaugh; Zachary J Hartley; Steven D Halter; James A David; Gregory Kapatos; Carl J Schmidt
Journal:  Neuropsychopharmacology       Date:  2014-03-19       Impact factor: 7.853

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.